Testing whether decision aids introduce cognitive biases: results of a randomized trial.
OBJECTIVE
Women at high risk of breast cancer face a difficult decision whether to take medications like tamoxifen to prevent a first breast cancer diagnosis. Decision aids (DAs) offer a promising method of helping them make this decision. But concern lingers that DAs might introduce cognitive biases.


METHODS
We recruited 663 women at high risk of breast cancer and presented them with a DA designed to experimentally test potential methods of identifying and reducing cognitive biases that could influence this decision, by varying specific aspects of the DA across participants in a factorial design.


RESULTS
Participants were susceptible to a cognitive bias - an order effect - such that those who learned first about the risks of tamoxifen thought more favorably of the drug than women who learned first about the benefits. This order effect was eliminated among women who received additional information about competing health risks.


CONCLUSIONS
We discovered that the order of risk/benefit information influenced women's perceptions of tamoxifen. This bias was eliminated by providing contextual information about competing health risks.


CONCLUSIONS
We have demonstrated the feasibility of using factorial experimental designs to test whether DAs introduce cognitive biases, and whether specific elements of DAs can reduce such biases.
Ubel
Peter A
PA
VA Health Services Research and Development Center of Excellence, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. paubel@med.umich.edu
Smith
Dylan M
DM
Zikmund-Fisher
Brian J
BJ
Derry
Holly A
HA
McClure
Jennifer
J
Stark
Azadeh
A
Wiese
Cheryl
C
Greene
Sarah
S
Jankovic
Aleksandra
A
Fagerlin
Angela
A
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000517:prevention & control*; D003071:Cognition; D032882:Comprehension; D003657:Decision Making; D003661:Decision Support Techniques; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008875:Middle Aged; D010353:Patient Education as Topic / Q000379:methods; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen